*<\/i>欧狄沃<\/i>^{[7]<\/span><\/sup>于2014年7月获批成为全球首个PD-1抑制剂，目前已在66个国家和地区获批共11个瘤种，涵盖肺癌、头颈癌、胃癌、食管癌、肝癌、肾癌、结直肠癌、尿路上皮癌、黑色素瘤、霍奇金淋巴瘤、胸膜肿瘤，惠及超过590,000名全球患者。<\/p> \n}

欧狄沃<\/i>是中国首个获批上市的免疫肿瘤药物，目前在中国获批共3项适应症，除下列以外其他适应证尚未获批：<\/p> \n

1)     用于治疗表皮生长因子受体（EGFR）基因突变阴性和间变性淋巴瘤激酶（ALK）阴性、既往接受过含铂方案化疗后疾病进展或不可耐受的局部晚期或转移性非小细胞肺癌（NSCLC）的成人患者；
2)     用于接受含铂类方案治疗期间或之后出现疾病进展且肿瘤PD-L1表达阳性（表达PD-L1的肿瘤细胞≥1%）的复发性或转移性头颈部鳞状细胞癌（SCCHN）患者；
3)     用于治疗既往接受过两种或两种以上全身性治疗方案的晚期或复发性胃或胃食管连接部腺癌患者。<\/p> \n

欧狄沃<\/i>是唯一由诺贝尔生理学或医学奖得主直接参与开发的PD-1抑制剂。百时美施贵宝拥有本庶佑博士的PD-1专利独家使用权。<\/p> \n

\n \n \n \n \n \n \n \n \n \n
[1] Opdivo Prescribing Information. Opdivo U.S. Product Information. Last updated: April 2021. Princeton, NJ: Bristol-Myers Squibb Company.<\/span><\/p> <\/td> \n <\/tr> \n
[2] Moehler M, Shitara K, Garrido M, et al. Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma: first results of the CheckMate 649 study. Late-breaker presented at: 2020 European Society for Medical Oncology (ESMO) Virtual Congress. September 19-21, 2020.<\/span><\/p> <\/td> \n <\/tr> \n
[3]Samson P and Lockhart AC. Biologic therapy in esophageal and gastric malignancies: current therapies and future directions. J Gastrointest Oncol. 2017;8(3):418-429.<\/span><\/p> <\/td> \n <\/tr> \n
[4] Murphy AG, Lynch D and Kelly RJ. State of the art management of metastatic gastroesophageal cancer. Ann Transl Med. 2015;3(16):236.<\/span><\/p> <\/td> \n <\/tr> \n
[5] Ai D, Zhu H, Ren W, et al. Patterns of distant organ metastases in esophageal cancer: a population-based study. J Thorac Dis. 2017;9(9):3023-3030.<\/span><\/p> <\/td> \n <\/tr> \n
[6] Nagaraja AK, Kikuchi O and Bass AJ. Genomics and targeted therapies in gastroesophageal adenocarcinoma. Cancer Discov. 2019;9(12):1656-1672.<\/span><\/p> <\/td> \n <\/tr> \n
[7] 注：欧狄沃<\/i>为基础的免疫单药治疗及免疫联合治疗方案<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p>"]; $("#dvExtra").html(content_array[0]);})();